** U.S.-listed shares of Canadian drugmaker jump 37 pct to $2.85 after FDA agrees to allow resubmission of marketing application for heart drug
** Stock is second among top advancers across U.S. exchanges
** Correvio formerly known as Cardiome Pharma says FDA also agrees to schedule a pre-marketing application meeting and expects it to take place in Q4
** Co’s heart drug Brinavess is approved for marketing in Europe and Canada
** Canada-listed shares also jumped nearly 42 pct
** Including sessions gains, U.S.-listed shares have nearly doubled in value YTD (Reporting by Shreyashi Sanyal in Bengaluru)
